Current Concepts for Diagnosing Non-Dysplastic and Dysplastic Barrett's Esophagus.

Matthew Stachler, Yekta Metanat, Joseph Willis

Abstract readReview

In one paragraph

Review in Gastrointestinal endoscopy clinics of North America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Matthew StachlerDepartment of Pathology, University of California San Francisco, UCSF Pathology, 505 Parnassus Avenue, San Francisco, CA 94143, USA.

Yekta MetanatDepartment of Pathology, University of California San Francisco, UCSF Pathology, 505 Parnassus Avenue, San Francisco, CA 94143, USA.

Joseph WillisDepartment of Pathology, University Hospitals Cleveland Medical Center/Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA. Electronic address: Joseph.Willis@Case.edu.

Funding

Optimization and validation of a biomarker panel for risk stratification in Barrett's esophagusR37CA269649 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Matthew D Stachler · 2023 to 2026

$2.6M

NCI NIH HHS R37 CA269649

6 · The paper itself

Abstract

Barrett's Esophagus (BE) is the precursor lesion of esophageal adenocarcinoma, which has a poor survival rate while having the fastest growing incidence of any cancer in the United States. Identifying patients with BE in the general population and optimizing surveillance programs to treat patients before the onset of adenocarcinoma are significant challenges. Clinical translation of advances in understanding BE pathogenesis and drivers of progression, along with improving pathologic diagnostic accuracy of precancerous lesions, holds promise to improve outcomes. This review highlights current concepts in BE-related surgical and molecular pathology and how these advances are being incorporated into daily clinical practice.

Indexed as

AdenocarcinomaBarrett EsophagusEsophageal NeoplasmsPrecancerous ConditionsDisease ProgressionEsophagoscopyEsophagusHumansBarrett’s esophagusDiagnosis of dysplasiaEsophagus adenocarcinomaPathologyProgression risk in Barrett’s esophagus

Identifiers

PMID41260768

DOI10.1016/j.giec.2025.05.007

PMCPMC13318404

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.